RHOA and breast carcinoma: Indeed, the migration-promoting effects and the enhanced RhoA/LIMK/Cofilin pathway induced by FMNL2 silencing could be abrogated by ZOL or BMS3, highlighting the involvement of RhoA/LIMK/Cofilin pathway in FMNL2-mediated inhibition of breast cancer cell migration and invasion.